“`html
Tempus AI Inc. has unveiled a clinically validated RNA-based algorithm test called PurIST, aimed at classifying pancreatic ductal adenocarcinoma (PDAC) tumors as either “classical” or “basal” subtypes. This development follows a real-world evidence study, published in JCO Precision Oncology, demonstrating PurIST’s role as both a prognostic and predictive biomarker for personalized first-line therapy in patients with advanced PDAC, which has a five-year survival rate of only 12%.
The global pancreatic cancer treatment market is expected to reach $5.84 billion by 2030, growing at a CAGR of 12.3% from 2025 to 2030, according to Grand View Research. Factors like unhealthy lifestyles and obesity contribute significantly to the prevalence of this cancer.
In the past year, Tempus AI shares have seen a growth of 67.4%, outperforming the industry’s 21.4% growth. Currently, Tempus AI has a forward Price-to-Sales ratio of 9.56, compared to the industry average of 5.88.
“`
